Hiki i ka lāʻau maʻi diabetes ke hoʻomaikaʻi i nā hōʻailona maʻi o Parkinson
ʻO Lixisenatide, he glucagon-like peptide-1 receptor agonist (GLP-1RA) no ka mālama ʻana i ka maʻi maʻi, e hoʻolōʻihi i ka dyskinesia i nā poʻe maʻi me ka maʻi maʻi o Parkinson, e like me nā hopena o kahi hoʻokolohua lapaʻau 2 i paʻi ʻia ma ka New England Journal of Medicine. NEJM) ma ka lā 4 ʻApelila 2024.
ʻO ke aʻo ʻana, alakaʻi ʻia e ka Halemai o ke Kulanui o Toulouse (Farani), ua kiʻi i nā kumuhana 156, i hoʻokaʻawale like ʻia ma waena o kahi hui lapaʻau lixisenatide a me kahi hui placebo.Ua ana nā mea noiʻi i ka hopena o ka lāʻau me ka Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score, me nā helu kiʻekiʻe ma ka pālākiō e hōʻike ana i nā maʻi ʻoi aku ka paʻakikī.Ua hōʻike ʻia nā hopena i ka mahina 12, ua emi iho ka helu MDS-UPDRS ʻāpana III e 0.04 mau helu (e hōʻike ana i ka hoʻomaikaʻi iki ʻana) i ka hui lixisenatide a hoʻonui ʻia e 3.04 mau helu (e hōʻike ana i ka piʻi ʻana o ka maʻi) ma ka hui placebo.
Ua hōʻike ʻia kahi mea hoʻoponopono NEJM i kēia manawa, ma ka ʻaoʻao, ua hōʻike kēia mau ʻikepili i ka lixisenatide i pale loa i ka piʻi ʻana o nā hōʻailona maʻi o Parkinson ma kahi o 12 mau mahina, akā he manaʻo maikaʻi loa paha kēia.ʻO nā unahi MDS-UPDRS a pau, me ka Māhele III, he mau unahi i hui pū ʻia me nā ʻāpana he nui, a ʻo ka hoʻomaikaʻi ʻana i kekahi ʻāpana ke pale aku i ka pōʻino o kekahi.Eia hou, ua pōmaikaʻi paha nā hui hoʻāʻo ʻelua ma ke komo ʻana i ka hoʻokolohua lapaʻau.Eia naʻe, ʻike ʻia nā ʻokoʻa ma waena o nā pūʻulu hoʻāʻo ʻelua, a kākoʻo nā hopena i ka hopena o ka lixisenatide i nā hōʻailona maʻi o Parkinson a me ka papa maʻi maʻi.
Ma ke ʻano o ka palekana, ʻo 46 ka nui o nā mea i mālama ʻia me ka lixisenatide i loaʻa i ka nausea a me ka 13 pākēneka i ʻike i ka luaʻi. ʻO ka hoʻemi ʻana i ka dosis a me nā ʻano hana hoʻomaha ʻē aʻe he mea waiwai.
"I loko o kēia ho'āʻoʻana,ʻo kaʻokoʻa o nā helu MDS-UPDRS he mea koʻikoʻi akā he liʻiliʻi ma hope o 12 mau mahina o ka mālamaʻana me ka lixisenatide. ʻO ke koʻikoʻi o kēiaʻikeʻaʻole i ka nui o ka hoʻololi, akā i ka mea i hōʻikeʻia."Ua kākau ka mea hoʻoponopono i ʻōlelo ʻia, "ʻO ka hopohopo nui no ka hapa nui o nā maʻi o Parkinson ʻaʻole ko lākou kūlana i kēia manawa, akā ʻo ka makaʻu i ka piʻi ʻana o ka maʻi. Ma kekahi ʻaoʻao, inā ʻoi aku ka maikaʻi o ka lixisenatide, e hoʻonui i ka helu ma kahi o 5 mau makahiki a i ʻole 10 mau makahiki a ʻoi aku paha kēia ʻO ka hana aʻe ka mea maopopo e hana i nā hoʻokolohua no ka lōʻihi."
Hoʻokumu ʻia e ka mea hana lāʻau lapaʻau Farani ʻo Sanofi (SNY.US), ua ʻae ʻia ka lixisenatide e ka US Food and Drug Administration (FDA) no ka mālama ʻana i ka maʻi maʻi type 2 i ka makahiki 2016, a lilo ia i ka 5th GLP-1RA e kūʻai ʻia ma ka honua. mai nā hoʻokolohua lapaʻau, ʻaʻole ia e like me ka maikaʻi o ka hoʻohaʻahaʻa ʻana i ka glucose e like me kona mau hoa liraglutide a me Exendin-4, a ʻo kona komo ʻana i ka mākeke US ma hope o kā lākou, e paʻakikī i ka huahana ke loaʻa kahi paʻa.I ka makahiki 2023, ua hoʻihoʻi ʻia ka lixisenatide mai ka mākeke US.Ua wehewehe ʻo Sanofi ma muli o nā kumu kūʻai aku ma mua o nā pilikia palekana a i ʻole nā pilikia me ka lāʻau lapaʻau.
ʻO ka maʻi o Parkinson kahi maʻi neurodegenerative e ulu nui ana ma waena o ka poʻe ʻelemakule a me ka poʻe ʻelemakule, ʻoi loa ka ʻike ʻia e ka haʻalulu hoʻomaha, ʻoʻoleʻa a me nā neʻe lohi, me kahi kumu ʻike ʻole.I kēia manawa, ʻo ke kumu nui o ka mālama ʻana i ka maʻi o Parkinson ʻo ka dopaminergic replacement therapy, ka mea nui e hoʻomaikaʻi i nā hōʻailona a ʻaʻohe hōʻike hoʻopono e pili ana i ka piʻi ʻana o ka maʻi.
Ua ʻike kekahi mau noiʻi mua e hoʻemi ana nā agonists receptor GLP-1 i ka mumū o ka lolo.ʻO ka neuroinflammation ke alakaʻi i ka nalowale holomua o nā pūnaeho lolo hana dopamine, kahi hiʻohiʻona koʻikoʻi o ka maʻi o Parkinson.Eia nō naʻe, ʻo ka GLP-1 receptor agonists wale nō i loaʻa i ka lolo ka maikaʻi i ka maʻi o Parkinson, a ʻo ka semaglutide a me ka liraglutide i kēia manawa, i ʻike nui ʻia no ko lākou hopena kaumaha, ʻaʻole i hōʻike i ka hiki ke mālama i ka maʻi o Parkinson.
Ma mua, ua ʻike ʻia kahi hoʻokolokolo i alakaʻi ʻia e kahi hui o nā mea noiʻi ma ka Institute of Neurology ma ke Kulanui o Lākana (UK) ʻo exenatide, ka mea i hoʻohālikelike ʻia me ka lixisenatide, i hoʻomaikaʻi i nā hōʻailona maʻi o Parkinson.Ua hōʻike ʻia nā hopena o ka hoʻokolokolo ma 60 mau pule, ua hoʻemi ʻia nā maʻi i mālama ʻia me exenatide i 1 mau helu i kā lākou mau helu MDS-UPDRS, aʻo ka poʻe i mālama ʻia me kahi placebo he 2.1-helu hoʻomaikaʻi.Hoʻokumu pū ʻia e Eli Lilly (LLY.US), kahi hui lāʻau lapaʻau nui o ʻAmelika, ʻo exenatide ka mua o ka honua GLP-1 receptor agonist, nāna i monopoli i ka mākeke no ʻelima mau makahiki.
Wahi a nā helu helu, ʻeono ma kahi o ʻeono mau agonist receptor GLP-1 i hoʻāʻo ʻia a i kēia manawa no ko lākou pono i ka mālama ʻana i ka maʻi o Parkinson.
Wahi a ka World Parkinson's Association, aia i kēia manawa he 5.7 miliona mau maʻi maʻi o Parkinson ma ka honua holoʻokoʻa, me kahi o 2.7 miliona ma Kina.Ma ka makahiki 2030, loaʻa iā Kina ka hapalua o ka heluna kanaka o Parkinson.E loaʻa i ka mākeke lāʻau lapaʻau maʻi Parkinson honua ke kūʻai aku ʻo RMB 38.2 biliona ma 2023 a ke manaʻo ʻia e hōʻea i RMB 61.24 biliona ma 2030, e like me ka DIResaerch (DIResaerch).
Ka manawa hoʻouna: Apr-24-2024
.png)
